{"id":"W4225994592","doi":"10.1016/j.jtocrr.2022.100324","title":"Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC","year":2022,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Roche; Novartis; Amgen; Pfizer; Les Laboratories Pierre Fabre; Novartis Pharmaceuticals Corporation; AstraZeneca; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Hazard ratio; Medicine; Trametinib; Internal medicine; Oncology; Confidence interval; Proportional hazards model; Vemurafenib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008616886,0.0002430603,0.001121363,0.0002047594,0.0001297266,0.00002343067,0.0002592222,0.000277541,0.00003465613],"category_scores_gemma":[0.0035126,0.0001698528,0.0002625145,0.0005172336,0.0008192091,0.00001193181,0.0005255151,0.001365071,6.812807e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006764654,"about_ca_system_score_gemma":0.001484405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002048865,"about_ca_topic_score_gemma":0.004069986,"domain_scores_codex":[0.992528,0.001966158,0.002544488,0.001160657,0.001230075,0.0005706723],"domain_scores_gemma":[0.996719,0.001090615,0.0005479517,0.0008009945,0.000498845,0.0003425847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2543817,0.001006917,0.7291397,0.00003284412,0.00009501312,0.0004859968,0.00005200184,0.00002824847,0.00000928672,0.00001786754,0.0001873316,0.01456308],"study_design_scores_gemma":[0.1210663,0.05444521,0.8094368,0.00007311909,0.00003414715,0.000007077561,0.000453714,0.000007600426,0.00008166847,0.00004487597,0.01403623,0.0003132636],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959848,0.0001251286,0.00000427241,0.0001438634,0.0006439267,0.001600758,0.00006332901,0.00001236796,0.001421532],"genre_scores_gemma":[0.9983872,0.0002301066,0.0004631524,0.00005431738,0.0001573742,0.0001449499,0.0002347189,0.00003642242,0.0002917981],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1333154,"threshold_uncertainty_score":0.6926396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07276526832441786,"score_gpt":0.4439244341244604,"score_spread":0.3711591658000425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}